Cost & Value of MedicinesShare the Savings

Patients share the costs for their medicines. They should share the savings, too.

Robust negotiations between biopharmaceutical companies and insurers often result in significant rebates and discounts. According to a recent study from the Berkeley Research Group, more than a third of the list price for brand medicines is rebated back to payers and the supply chain.

However, unlike care received at an in-network hospital or physician’s office, negotiated discounts for medicines are not shared with patients with high deductibles or coinsurance. A new analysis from Amundsen Consulting found more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price. 

Insurers should share more of these rebates with patients.  Providing access to discounted prices at the point-of-sale could dramatically lower patients’ out-of-pocket costs.

Get the facts and find out where the discounts are going.

 

Ads

Ads

Graphics

Reports

Reports

Latest From TheCatalyst Blog

IP Explained: Why IP protections are important for biologic medicines

By Tom Wilbur on July 18, 2019

Myvideopays member companies invested nearly $80 billion in R&D last year

By Tim McClung on July 18, 2019

Setting the record straight on international reference pricing

By Kevin Haninger on July 16, 2019

New Let's Talk About Cost TV ad asks: Why aren't patients sharing in savings at the pharmacy counter?

By Priscilla VanderVeer on July 9, 2019
http://steroid-pharm.com

https://biceps-ua.com

www.medicaments-24.net/viagra-sildenafil/viagra-50-mg/